• GeneDx Holdings Corp WGS.OQ reported quarterly adjusted earnings of 27 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of six analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from 1 cents to 11 cents per share.

• Revenue rose 40.3% to $85.76 million from a year ago; analysts expected $79.47 million.

• GeneDx Holdings Corp's reported EPS for the quarter was a loss of 23 cents​.

• The company reported a quarterly loss of $6.53 million.

• GeneDx Holdings Corp shares had risen by 32.1% this quarter and gained 52.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

• Wall Street's median 12-month price target for GeneDx Holdings Corp is $109.50

This summary was machine generated from LSEG data April 30 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)